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Mortality rates following repair of ruptured abdominal
aortic aneurysms have remained depressingly high over the
last number of decades despite advances in anesthesia and
perioperative care. Prior to the introduction of endovas-
cular repair, refinements in surgical technique had been
few and far between. It was not until fairly recently that we
finally observed a reduction in mortality coinciding with the
wider adoption of endovascular repair. So, the case is
closed, right? Endovascular repair should be widely adopted
in all suitable patients? Well . not exactly. The following
debate centers around what level of evidence is required to
answer this question.
Frank Veith argues that we’re already there. He was an
early adopter and innovator of endovascular techniques
and feels that we have enough information to widely adopt
endovascular repair of ruptured aneurysms. Janet Powell
and Robert Hinchliffe, innovators in their own right, feel
that the generalizability and applicability of endovascular
repair require further evaluation with a randomised trial.
Both offer clear and reasoned arguments.DOI of original article: 10.1016/j.ejvs.2010.06.022, 10.1016/
j.ejvs.2010.06.005
* This paper is alsobeingpublished in theJournal ofVascular Surgery.
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Should the potential benefits and risks of endovascular
repair of ruptured abdominal aortic aneurysm (rAAA) on
apopulation-basedornational scalebeevaluatedbyevidence
or by expert opinion? By evidence, of course, with the best
evidence coming from randomised controlled trials (RCTs).
The evaluation and assessment of the role of endovas-
cular repair for ruptured aneurysm depends on numerous
factors including the patient’s physiological condition and
anatomy, the decision to intervene, the skills of the oper-
ators and their teams, learning curves, the availability of
endovascular aneurysm repair (EVAR) in different centres
and the perception of equipoise. A few well-equipped and
well-organised pioneering centres report excellent results
with endovascular repair. Similarly a few pioneering
centres report excellent results for elective laparoscopic
repair of aneurysms. However, in neither case is there yet* Corresponding author. Tel.: þ44 208 846 7312; fax: þ44 208
8467330.
E-mail address: j.powell@imperial.ac.uk (J.T. Powell).
Table 1 The IDEAL1 recommendations and endovascular repair of ruptured abdominal aortic aneurysm.
Stage1 Description Citation
Innovation First case described Yusuf et al., 19942
Development Protocols developed & associated problems
addressed in a handful of centres
Mayer et al 20093
Mayer et al 20094
Malina et al5
Exploration Pilot RCTExploratory analysis of national
data base
Hinchliffe et al., 200610
Egorova et al., 200811
Holt12
Assessment AJAX, ECAR, IMPROVE RCTs in progress Trialists14e16
Long-term follow up Currently limited to case series Hinchliffe et al13
RCT, randomised controlled trial. Text in italics are stages not completed.
422 J.T. Powell, R.J. Hinchliffegood quality evidence to support the widespread adoption
of these practices.
The recent IDEAL (Innovation-Development-Exploration-
Assessment-Long-term follow up) recommendations have set
out the essential stages in the introduction of innovative
surgical techniques into widespread practice: “No surgical
innovation without evaluation”.1 These are the recommen-
dations (see Table 1) that healthcare policy makers and
commissioners will use as a guide to evaluate the utility of
EVAR for rAAA. The Innovationwas reported in 19942 and since
then Development of EVAR for rAAA has occurred in a few
centres, Zurich, New York and Malmo¨ (Table 1).3e5 The
Development has resulted in specific protocols, which include
use of aortic occlusion balloons to permit rapid haemorrhage
control and the open abdomen technique to avoid the
damaging effects of compartment syndrome. New technolo-
gies and procedures in patients must be reported, whether
successful or not.1,6 However, with EVAR for rAAA there has
been a tendency only to report successful procedures, with
most case series reporting favourable results.7 Publication
bias leads to unfavourable results not being reported. In
addition, the selection of patients is poorly reported in cohort
studies and in some there is no discrimination between urgent
and ruptured aneurysms. Case selection may underlie
the impressive resultsachieved in specialist centresusingboth
EVAR and open repair: some centres report a very low
mortality from open repair of ruptured aneurysm but in
general the results remain disappointing with around 40-50%
peri-operative mortality.8,9 The sequential reporting of all
cases (endovascular and open) may unmask some of the
case selection bias and a standardised format for reporting
would facilitate assessment of major co-morbidities and
confounders.6 Unfortunately no standardised reporting
format for the outcome of rAAA has been developed.
TheExploratoryphase of IDEAL is basedon the reporting of
the first few hundred cases in both prospective research
databases and exploratory randomised trials: the data from
such studies provide the information base for the Assessment
phase. The only pilot randomised trial demonstrated the
feasibility of randomising patients in the emergency situation
and highlighted many of the organisational difficulties.10
Intriguingly 30 day mortality was not different in those
undergoing either open surgery or EVAR.10 The results of
publically-funded randomised trials are always reported,
whether favourable or not. The Medicare data set in the USA
and the Hospital Episode Statistics (HES) data in the UK have
been inspected foroutcomesandshowedbetteroutcomes forendovascular repair thanopen repair,with 30-daymortalities
of about 21e30% reported.11,12 Such studies suffer from
strong patient selection bias and confounders cannot be
eliminated and the patient cohorts likely include both urgent
(symptomatic) and ruptured aneurysms. Currently there is
a paucity of data on the long-term outcomes of patients
having undergone emergency endovascular repair, although
the Zurich group have presented data on 5-year outcomes at
theEuropean Surgical Association soon [Budapest,May 2010].
There are suspicions regarding the durability of stent-grafts
and the number of secondary interventions may be signifi-
cant.13 A life-saving parachute (open repair) has existed for
patients with ruptured aneurysm for over 50 years. The
question now is which design of parachute (open repair or
stent) is a better buy? Assessment is essential and RCTs will
confirm which parachute is the best buy.
TheRCTis thegold-standard for theAssessmentof surgical
innovations. There are two main types of RCTs. There are
exploratory trials which seek to assess whether an interven-
tion or surgical procedure can work, such as the AJAX and
ECAR trials for rAAA.14,15 Their results will add to the Devel-
opment evidence from specialist centres.3e5 There also are
large, pragmatic multi-centre trials with cost-effectiveness
evaluations, which seek to inform clinical policy and decision
making for populations and here the IMPROVE trial is the
example for rAAA.16 Such trials should be followed by Long-
term monitoring to report on any delayed adverse events.
The only other evidence currently available about the
potential benefits of EVAR for rAAA comes from systematic
reviews and meta-analyses of published cohort studies
which suffer from heterogeneity, under-reporting of poor
results and inadequate adjustment for confounders.7 These
systematic reviews cannot be considered adequate
evidence, as recognised by most of their authors who
conclude with the demand for a randomised trial. The
morphological limitations of EVAR, with perhaps only about
60% of ruptured aneurysms having suitable anatomy, the
willingness of clinicians to transfer a patient to the CT
scanner when they are actively haemorrhaging, uncertainty
about the true physiological effects of endovascular repair
including compartment syndrome, contrast induced renal
failure and the consequences of endoleak, patient
outcomes from non-expert centres, the paucity of data on
patients turned down for any intervention and a lack of
standardised reporting criteria are issues that cannot be
addressed adequately by single centre experiences, data-
bases designed for routine administrative purposes or
Table 2 Expert centre case series versus randomised controlled trials for the Assessment of endovascular repair for ruptured
aneurysm.
Case series Large multi-centre RCT Benefit of RCT
Pre-operative care Inconsistent Algorithms of care
(eg permissive hypotension,
imaging)
Improves care for all patients
and reduces bias
Patients turned down
for intervention
Rarely captured Captured Allows reporting of generalisibility
Patient selection Most stable & morphologically
suitable patients from defined
geographical areas
Unselected Prevents more stable and
morphologically easy cases being
cherry picked for EVAR
Patient co-morbidities Not fully reported, source of
major bias
Proforma reporting &
balanced by randomisation
Reduces bias
Unknown patient
factors
Source of confounding Balanced by randomisation Reduces bias
Imaging No data on those
morphologically unsuitable
for EVAR or deaths in CT scan
Data on aneurysm
morphology & any
adverse effects of CT.
Data on proportion of rAAA suitable
for EVAR and evidence of any harm
in CT (delay)
Core laboratory reporting Reduces bias
Intervention Expert teams Captures national diversity Allows translation of findings
Other clinical factors
& provision of
services (critical
care, nursing etc)
Special facilities & staffing Captures national diversity Allows translation of findings
Primary outcome No pre-specified end-point Pre-specified Trial powered to avoid type II error
Complications/
secondary outcomes
& patient quality of
life
No proforma reporting: often
retrospective, poorly recorded,
with missing data
Pre-defined, standardised &
recorded prospectively
Key information on complications &
adverse outcomes, essential for
cost-effectiveness evaluation
Sub-group analysis Ad hoc Prespecified, identification
of subgroups who benefit
Allows translation & reduces bias
Economic analysis Retrospective difficult to
capture complications
Population-based resources
used recorded prospectively
Cost effective analysis necessary for
healthcare change
Reporting Publication bias for positive
results
Reported irrespective of
results
Reduces bias
Generalisability Low as often only performed
in specialised centres
High as multi-centre trial
including centres which
are not hyper-specialist
Technique applicable to non-expert
centres.
Long-term outcome Frequent loss to follow-up Patients followed-up
prospectively
Risk-benefit analysis
Part One: For the Motion 423systematic reviews (Table 2). In contrast, large pragmatic
multi-centre randomised trials can address all these issues.
History is full of examples where the conclusions drawn
from observational studies have been overturned by RCTs.
Our opponent has had direct experience of this in the use of
PTFE grafts for critical limb ischaemia.17,18 The amazing
results of absorbable metal stents on the treatment of
critical limb ischaemia were overturned by an RCT.19,20
Other examples taken from outside vascular surgery,
where large pragmatic RCTs have overturned the findings
from observational studies include the CRASH trial of
corticosteroids in acute head injury and the randomised
trial of estrogen plus progestin for secondary prevention of
cardiovascular events in postmenopausal women.21,22
Large pragmatic trials, like IMPROVE, take account of
a number of features which may be unique to surgical trials,
including imbalance in surgical and associated expertise,
variation in standards of general healthcare and cardiovas-
cular risk prevention, which are particularly relevant in thearea of vascular surgery and ruptured aneurysm, variation in
the standards of aftercare, including nursing and rehabilita-
tion. For trials of emergency surgery there are other issues,
including geographical provision of services, distance the
patient travels to an emergency centre, anaesthetic exper-
tise, access to critical care facilities, transfer and financial
arrangements. None of these issues are addressed by cohort
studies, systematic reviewsofcohort studiesoradministrative
databases. In contrast, these real life service andpolicy issues
can be addressed by large, multi-centre randomised trials
(Table 2). Moreover, only data from the randomised trials or
mandatory registries will give us good reporting of the long-
term balance of risks and benefits and whether any early
survival advantage is maintained.
In conclusion, the Exploratory phase of endovascular
repair for ruptured AAA, the only pilot trial has shown no
difference in 30-day mortality between endovascular and
open repair.10 The AJAX trial14 is being extended because
the results of endovascular repair were not as good as
* Author at 4455 Douglas Ave, Suite 11E, Bronx, NY, 10471, USA.
Tel.: þ1 718 549 3140.
424 F.J. Veithanticipated from the literature. Irrespective of the reports
of the good outcomes after endovascular repair from single
expert centres or administrative databases, all these
results are heavily confounded by patient selection and
risks are under-reported. We need better evidence to
guarantee the best outcomes for future patients with
aneurysm rupture. We need to know whether an attempt at
endovascular repair would be beneficial for all patients. It
is only such knowledge that will drive changes in the
provision of healthcare services to benefit future patients.
The front cover of the Lancet issue of 26th September 2009,
which published the IDEAL statements, carried this sen-
tence: “It is incumbent on academic surgeons worldwide to
transform what was once considered a comic opera into
a dynamic world-class specialty”. We need to assess
surgical innovations, including endovascular repair for
ruptured aneurysm, rapidly in large, pragmatic RCTs.
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